eFFECTOR Therapeutics is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs known as selective translation regulator inhibitors (STRIs). Translation is the process in cells whereby the synthesis of proteins is directed by information contained in genetic sequences. Our targets lie downstream from two of the most frequently mutated signaling pathways in cancer—the RAS and PI3K pathways—and are responsible for the selective translation of mRNA into proteins, which are frequent culprits in key disease-driving processes. Each of our product candidates is designed to act on a single protein that regulates, in a coordinated manner, the expression of multiple functionally related proteins that together drive tumor cell proliferation and survival, cell cycle progression and important biological processes such as immune and inflammatory responses.
In cancer, the tightly controlled translation of certain messenger RNA (mRNA) frequently becomes upregulated, leading to malignancy characterized by uncontrolled growth, immune evasion and metastasis. We believe that our therapeutic approach can inhibit the production of key disease-driving proteins, which tumors have hijacked for their benefit and are highly sensitive to their inhibition, all while preserving normal cell function.